Tim Hugo Maria Jonckers

This inventor holds 78 USPTO granted patents and 17 published patent applications, plus 25 CIPO patents and 49 EPO patents, primarily in Viral Infection Treatment (CPC class C07D). Top assignees: Janssen Sciences Ireland Uc, Janssen Sciences Ireland Unlimited Company, Katholieke Universiteit Leuven. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tim Hugo Maria Jonckers. Retrieved from https://idiyas.com/inventor/tim-hugo-maria-jonckers

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 78 (Patent Applications = 17)

% Patents Active = 66.7

CIPO Patents = 25 (Patent Applications = 13)

EPO Patents = 49 (Patent Applications = 64)

Average Co-Inventor Count = 5.6

ph-index = 17

Forward Citations = 660(Granted Patents)

Forward Citations (Not Self Cited) = 404(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Mechelen, BE (2013)
Edegem, BE (2010 - 2018)
Heist-op-den-Berg, DE (2019)
Heist-op-den-Berg, BE (2014 - 2023)
Beerse, BE (2018 - 2023)

Company Filing History:

35 out of 111

Janssen Sciences Ireland Uc

patents

14 out of 64

Janssen Sciences Ireland Unlimited Company

patents

10 out of 631

Katholieke Universiteit Leuven

patents

4. 9 out of 161

Janssen Pharmaceuticals, Inc.

Tibotec Pharmaceuticals Ltd.

patents

9. 1 out of 2,101

Janssen Pharmaceutica Nv

patents

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

Dengue Viral Replication Inhibitors

Pyrimidine Derivatives

Indole Derivatives

Quinoxalinones

Aryl Substituted Pyrimidines

Spirothietane Nucleosides

Pyrrolo[3,2-d]pyrimidine

HBV Infection Treatment

Heterocyclic Substituted

Uracyl Spirooxetane

Piperidine Substituted

Respiratory Syncytial Virus

78 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12702657 - Treatment and prevention of dengue disease (2026-08-11),

2. 12172959 - Mono- or di-substituted indole derivatives as dengue viral replication inhibitors (2024-12-24),

3. 11827602 - Mono- or di-substituted indole derivatives as dengue viral replication inhibitors (2023-11-28),

4. 11597704 - 2,4-diaminoquinazoline derivatives and medical uses thereof (2023-03-07),

5. 11541050 - Pyrimidine derivatives for the treatment of viral infections (2023-01-03),

6. 11491148 - Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases (2022-11-08),

7. 11267844 - Spirothietane nucleosides (2022-03-08),

8. 11220504 - Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases (2022-01-11),

9. 11117887 - Aryl substituted pyrimidines for use in influenza virus infection (2021-09-14),

10. 11096931 - Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases (2021-08-24),

11. 11053256 - Dihydropyranopyrimidines for the treatment of viral infections (2021-07-06),

12. 10968184 - Pyrimidine prodrugs for the treatment of viral infections and further diseases (2021-04-06),

13. 10919854 - Mono- or di-substituted indole derivatives as dengue viral replication inhibitors (2021-02-16),

14. 10786484 - Mono- or di-substituted indole derivatives as dengue viral replication inhibitors (2020-09-29),

15. 10781216 - Pyrrolo [3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases (2020-09-22),

Title: Tim Hugo Maria Jonckers - Innovator in Dengue Viral Research

Introduction

Tim Hugo Maria Jonckers, based in Heist-op-den-Berg, Belgium, is a prominent inventor known for his significant contributions to the field of medical research. With an impressive portfolio of 77 patents, his work primarily focuses on the development of novel compounds aimed at combating viral infections, particularly dengue fever.

Latest Patents

Among his latest innovations, Jonckers has developed mono- or di-substituted indole derivatives that serve as dengue viral replication inhibitors. This groundbreaking invention outlines methods to prevent or treat dengue viral infections using these compounds. Moreover, the invention includes formulations of pharmaceutical compositions geared towards the effective treatment or prevention of dengue infections. The research emphasizes the importance of these compounds as potential medicines and provides detailed processes for their preparation.

Career Highlights

Jonckers has made substantial strides in his career by collaborating with leading pharmaceutical companies. Notably, he has been affiliated with Janssen Sciences Ireland UC and Janssen Sciences Ireland Unlimited Company, where he contributed to innovative research that enhances disease treatment options.

Collaborations

Throughout his professional journey, Tim has had the privilege of working alongside esteemed colleagues, including Pierre Jean-Marie Bernard Raboisson and Abdellah Tahri. These collaborations reflect the collective effort in scientific advancements that aim to improve public health.

Conclusion

In conclusion, Tim Hugo Maria Jonckers stands out as an influential inventor in the realm of antiviral research. His pioneering patents and collaborative work continue to shape the future of medical innovations, particularly in the fight against dengue viral infections. His contributions highlight the critical intersection of research and practical applications in healthcare, marking him as a significant figure in the industry.

Profile summary based on public USPTO records.